Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study

Psycho-Oncology

Volumn 21, Issue 5, 2012, Pages 479-487

  Schilder, C M T ^a   Seynaeve, C ^b   Linn, S C ^c   Boogerd, W ^c,d   Beex, L V A M ^e   Gundy, C M ^a   Nortier, J W R ^f   Van De Velde, C J H ^f   Van Dam, F S A M ^a   Schagen, S B ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d Slotervaart Medical Center   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer; cancer; endocrine therapy; oncology; self reported cognitive functioning; subjective cognitive functioning

Indexed keywords

EXEMESTANE; TAMOXIFEN;

AGED; ANXIETY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; COGNITION; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MENTAL CONCENTRATION; NEUROPSYCHOLOGY; POSTMENOPAUSE; QUESTIONNAIRE; REVIEW; SELF REPORT; TASK PERFORMANCE;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; DEPRESSION; FEMALE; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT; TAMOXIFEN;

EID: 84860223548     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1928     Document Type: Review

References (58)

1. Shilling V, Jenkins V,. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11: 6-15.
2. Debess J, Riis JO, Pedersen L, Ewertz M,. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol 2009; 48: 532-540.
3. Schagen SB, Das E, van Dam FS,. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psycho-Oncology 2009; 18: 674-678.
4. Weis J, Poppelreuter M, Bartsch HH,. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psycho-Oncology 2009; 18: 775-782.
5. Pullens MJ, De VJ, Roukema JA,. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology 2010; 19: 1127-1138.
6. Jonker C, Geerlings MI, Schmand B,. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000; 15: 983-991.
7. Westoby CJ, Mallen CD, Thomas E,. Cognitive complaints in a general population of older adults: prevalence, association with pain and the influence of concurrent affective disorders. Eur J Pain 2009; 13: 970-976.
8. Tannock IF, Ahles TA, Ganz PA, Van Dam FS,. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22: 2233-2239. (Pubitemid 41095159)
9. Bender CM, Pacella ML, Sereika SM, et al., What do perceived cognitive problems reflect? J Support Oncol 2008; 6: 238-242. (Pubitemid 351836613)
10. Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650. (Pubitemid 29075285)
11. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S,. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004; 13: 61-66. (Pubitemid 38139358)
12. Middleton LS, Denney DR, Lynch SG, Parmenter B,. The relationship between perceived and objective cognitive functioning in multiple sclerosis. Arch Clin Neuropsychol 2006; 21: 487-494. (Pubitemid 44247524)
13. Lannoo E, Colardyn F, Vandekerckhove T, De Deyne C, De Soete G, Jannes C,. Subjective complaints versus neuropsychological test performance after moderate to severe head injury. Acta Neurochir(Wien) 1998; 140: 245-253. (Pubitemid 28192894)
14. Velissaris SL, Wilson SJ, Newton MR, Berkovic SF, Saling MM,. Cognitive complaints after a first seizure in adulthood: influence of psychological adjustment. Epilepsia 2009; 50: 1012-1021.
15. Bedi G, Redman J,. Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean? J Psychopharmacol 2008; 22: 872-881.
16. Vestberg S, Passant U, Elfgren C,. Stability in the clinical characteristics of patients with memory complaints. Arch Gerontol Geriatr 2010; 50:e26-e30.
17. Weaver Cargin J, Collie A, Masters C, Maruff P,. The nature of cognitive complaints in healthy older adults with and without objective memory decline. J Clin Exp Neuropsychol 2008; 30: 245-257.
18. Reid LM, Maclullich AM,. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 2006; 22: 471-485. (Pubitemid 44726019)
19. Lai JS, Butt Z, Wagner L, et al., Evaluating the dimensionality of perceived cognitive function. J Pain Symptom Manage 2009; 37: 982-995.
20. Pearman A, Storandt M,. Self-discipline and self-consciousness predict subjective memory in older adults. J Gerontol B Psychol Sci Soc Sci 2005; 60: 153-157.
21. Servaes P, Verhagen S, Bleijenberg G,. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 2002; 13: 589-598. (Pubitemid 34461143)
22. McDonald-Miszczak L, Hertzog C, Hultsch DF,. Stability and accuracy of metamemory in adulthood and aging: a longitudinal analysis. Psychol Aging 1995; 10: 553-564. (Pubitemid 26113153)
23. Christodoulou C, Melville P, Scherl WF, et al., Perceived cognitive dysfunction and observed neuropsychological performance: longitudinal relation in persons with multiple sclerosis. J Int Neuropsychol Soc 2005; 11: 614-619. (Pubitemid 41478995)
24. Lezak M., Neuropsychological Assessment. Oxford University Press: New York, 2004.
25. van Nes JG, Seynaeve C, Maartense E, et al., Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Ann Oncol 2010; 21: 974-982.
26. Schilder CM, Seynaeve C, Beex LV, et al., Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010; 28: 1294-1300.
27. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S,. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 2009; 18: 811-821.
28. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ,. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008; 9: 953-961.
29. Cella D, Land SR, Chang CH, et al., Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 2008; 109: 515-526. (Pubitemid 351692068)
30. Schilder CM, Eggens PC, Seynaeve C, et al., Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48: 76-85.
31. Van der Meulen EF, Schmand B, van Campen JP, et al., The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004; 75: 700-705. (Pubitemid 38526679)
32. Ponds RW, Roozendaal N, Jolles J,. 2004. The Cognitive Failure Questionnaire: Factor Structure, Effects of Age, Sex and Education and the Relation with Cognitive Performance and Psychosocial Variables. University of Maastricht: Maastricht.
33. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR,. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982; 21 (Pt 1): 1-16. (Pubitemid 12093480)
34. Huyser Y., De symptomatologie van depressieve stoornissen en angststoornissen. Benecke Consultants: Amsterdam, 2004.
35. Van Dam FS, Schagen SB, Muller MJ, et al., Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218. (Pubitemid 28114539)
36. Frojdh K, Hakansson A, Karlsson I,. The Hopkins Symptom Checklist-25 is a sensitive case-finder of clinically important depressive states in elderly people in primary care. Int J Geriatr Psychiatry 2004; 19: 386-390. (Pubitemid 38461079)
37. Aaronson NK, Ahmedzai S, Bergman B, et al., The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
38. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D,. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999; 55: 189-199. (Pubitemid 29389581)
39. van den Burg W, Saan RJ, Deelman BG,. 15-Woordentest. Provisional Manual. University Hospital, Department of Neuropsychology: Groningen, 1985.
40. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C,. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002; 73: 126-133.
41. Wechsler D,. Wechsler Memory Scale: Revised. Psychological Corporation: New York, 1987.
42. Reitan R,. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
43. Hammes J,. De Stroop Kleur-Woord Test. Handleiding (2nd edn). Swets & Zeitlinger: Lisse, 1978.
44. Wechsler D,. WAIS-III Nederlandstalige Bewerking. Technische Handleiding. Swets & Zeitlinger: Lisse, 2000.
45. Alpherts W, Aldenkamp AP,. FePsy: The Iron Psyche. Instituut voor Epilepsiebestrijding: Heemstede, 1994.
46. Van der Elst W, van Boxtel MP, Van Breukelen GJ, Jolles J,. Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006; 12: 80-89. (Pubitemid 43379954)
47. Schmand B, Groenink SC, van den Dungen M,. [Letter fluency: psychometric properties and Dutch normative data] Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr 2008; 39: 64-76. (Pubitemid 351753744)
48. Schmand B, Lindeboom J, van Harskamp F,. De Nederlandse Leestest voor Volwassenen. Swets & Zeitlinger: Lisse, 1992.
49. Schilder CM, Seynaeve C, Linn SC, et al., Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 2010; 76: 133-141.
50. Schilder CM, Seynaeve C, Linn SC, et al., The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psycho-Oncology 2010; 19: 415-422.
51. Pfeifer S, van Os J, Hanssen M, Delespaul P, Krabbendam L,. Subjective experience of cognitive failures as possible risk factor for negative symptoms of psychosis in the general population. Schizophr Bull 2009; 35: 766-774.
52. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M,. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 1996; 74: 1674-1679. (Pubitemid 26386101)
53. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26: 955-969. (Pubitemid 39577316)
54. Minisini AM, De Faccio S, Ermacora P, et al., Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 2008; 67: 71-79.
55. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C,. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17: 122-130. (Pubitemid 351279862)
56. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA,. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004; 101: 466-475.
57. Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, der Maase H,. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009; 15: 296-301.
58. Schagen SB, Vardy J,. Cognitive dysfunction in people with cancer. Lancet Oncol 2007; 8: 852-853. (Pubitemid 47488056)